Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rapt Therapeutics Inc (NQ: RAPT ) 1.850 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Rapt Therapeutics Inc < Previous 1 2 Next > RAPT Therapeutics Reports Second Quarter 2024 Financial Results August 08, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm May 09, 2024 From Schall Law Via GlobeNewswire RAPT Therapeutics Reports First Quarter 2024 Financial Results May 09, 2024 Company maintains solid cash position of $141.6 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients April 09, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm March 11, 2024 From Bragar Eagel & Squire Via GlobeNewswire RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 07, 2024 Company maintains solid cash position of $158.9 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting March 05, 2024 Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings February 26, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon February 20, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations February 13, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy November 27, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Reports Third Quarter 2023 Financial Results November 13, 2023 Company maintains strong cash position of $184.8 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC November 03, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November November 01, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting October 18, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September August 30, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Reports Second Quarter 2023 Financial Results August 11, 2023 Company maintains strong cash position of $205 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference June 07, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers May 25, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Reports First Quarter 2023 Financial Results May 11, 2023 Company maintains strong cash position of $231.6 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel May 03, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 26, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma March 29, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results March 14, 2023 Company maintains strong cash position of $249.1 million From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference February 07, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer December 08, 2022 Data Presented at ESMO Immuno-Oncology Congress From RAPT Therapeutics, Inc. Via GlobeNewswire RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress November 30, 2022 From RAPT Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.